Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.

Thrombosis research - 1 Feb 2013

Skov Jane, Bladbjerg Else-Marie, Leppin Anja, Jespersen Jørgen

Abstract excerpt

INTRODUCTION: A substantial part of the inter-individual variation in vitamin K-antagonist dose can be explained by certain sequence variants in the genes CYP2C9 (NG_008385.1:g.8633C>T or *1/*2, NG_008385.1:g.47639A>C or *1/*3) and VKORC1 (NG_011564.1:g.6399C>T). Patients possessing these variant alleles require lower doses and have increased risk of overanticoagulation. METHODS: We investigated the influence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 23159229
DOI: 10.1016/j.thromres.2012.11.004

Genes

TTR
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.PMID 23159229Read ↗

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.Semantic proximity Read ↗

CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation.Semantic proximity Read ↗

VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.Semantic proximity Read ↗

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.Semantic proximity Read ↗

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.Semantic proximity Read ↗

Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.Semantic proximity Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.